UNSPSC 51351703: Methallenestril

This classification denotes a non-steroidal estrogen with the molecular formula C18H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XL025389JS, chemically known as 3-(6-methoxy-2-naphthyl)-3-ethyl-2,2-dimethylpropionsaeure but generally known as methallenestril, which bears US NIH Compound Identifier 10599. European Medicines Agency schedules Methallenestril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08834MIG.

UNSPSC 51351703 Methallenestril is a Commodity code that captures pharmaceutical products supplied through state and local cooperative purchasing frameworks. The code reflects actual procurement activity: the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued a Request for Proposal to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. Vendors supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Scoring weights price competitiveness at 75 percent, with the remainder distributed across fixed pricing, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place and carry commercial general liability coverage of $5,000,000 per occurrence alongside network security and professional liability coverage of $2,000,000 each.

The MMCAP RFP (S1070000015802) with a March 26, 2026 response date represents the primary recent opportunity under this code. The contract term spans two years for new vendors, with optional extensions at MMCAP's discretion, and incumbent vendors' amendments align with existing expiration dates through June 30, 2028. Products must be available in the marketplace by May 15, 2026, when awarded vendors will be provided to authorized wholesalers with resulting agreements effective July 1, 2026. Submissions require detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations, all formatted as Excel spreadsheets converted to CSV and submitted through the ePro procurement system. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. The solicitation does not identify specific set-aside designations or business-classification restrictions based on available documentation.